The role of menopausal hormone therapy in osteoporosis.
Potential adverse effects limit the therapeutic envelope of hormone therapy as regards its effect on bone. This envelope can be enlarged considerably by targeting the younger patient at risk of fracture at the lowest dosage with an appropriate route of administration.
de Villiers
T
T
Panorama MediClinic, Parow, South Africa.
D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D015914:Estrogen Replacement Therapy; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016387:Women's Health
D050071:Bone Density Conservation Agents